Niantic, CT, United States of America

Douglas Charles Hanson

USPTO Granted Patents = 12 


 

Average Co-Inventor Count = 6.1

ph-index = 8

Forward Citations = 450(Granted Patents)


Company Filing History:


Years Active: 1993-2018

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Innovations of Douglas Charles Hanson

Introduction

Douglas Charles Hanson is a notable inventor based in Niantic, Connecticut, with a remarkable portfolio of 12 patents. His work primarily focuses on advancements in biotechnology, particularly in the development of human monoclonal antibodies.

Latest Patents

One of Hanson's latest patents includes the invention of fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). This patent provides nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules. Specifically, it details contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), particularly from within FR1 and/or CDR1 through CDR3 and/or within FR4. The patent further includes antibodies with similar binding properties and functionality as those disclosed.

Career Highlights

Throughout his career, Douglas has made significant contributions while working with prominent companies such as Pfizer Corporation and Amgen Fremont Inc. His expertise in the field of immunology and biotechnology has led to innovative solutions that enhance therapeutic options.

Collaborations

Some of his notable coworkers include Mark Joseph Neveu and Eileen Elliott Mueller, who have collaborated with him on various projects.

Conclusion

Douglas Charles Hanson is a distinguished inventor whose work in monoclonal antibodies has the potential to impact the field of immunotherapy significantly. His contributions continue to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…